Stocktoria
NovoCure Ltd NVCR
NovoCure Ltd (NVCR) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $655.4M at a -20.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.27 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-18 | HC Wainwright & Co. | Buy (reit) |
| 2026-05-04 | Wells Fargo | Equal-Weight (main) |
| 2026-05-01 | Evercore ISI Group | Outperform (main) |
| 2026-04-16 | Wedbush | Neutral (reit) |
| 2026-02-26 | HC Wainwright & Co. | Buy (main) |
| 2026-02-12 | HC Wainwright & Co. | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.527 |
| Retained earnings / assets | -1.604 |
| EBIT / assets | -0.191 |
| Equity / liabilities | 0.734 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NVCR | NovoCure Ltd | 3/9 | -2.29 | — | +8.3% |
| UFPT | UFP TECHNOLOGIES INC | 7/9 | 6 | 28.7 | +19.5% |
| BVS | Bioventus Inc. | 8/9 | 0.54 | 35.9 | -0.9% |
| IRTC | iRhythm Holdings, Inc. | 5/9 | 0.78 | — | +26.2% |
| ATEC | Alphatec Holdings, Inc. | 6/9 | -4.63 | — | +25% |
| ATRC | AtriCure, Inc. | 7/9 | 3.44 | — | +14.9% |
| GKOS | GLAUKOS Corp | 2/9 | 0.74 | — | +32.3% |
About NovoCure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
FAQ
Is NVCR financially healthy?
NovoCure Ltd's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does NVCR pay a dividend?
No, NovoCure Ltd does not currently pay a dividend.
How profitable is NVCR?
In FY2025, NovoCure Ltd had a net margin of -20.8% and a return on equity of -40.0%.
What is the analyst price target for NVCR?
The average Wall-Street price target for NovoCure Ltd is $26.00, about 47.8% above the recent price, from 7 analysts (consensus: buy).
Is NVCR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NovoCure Ltd: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.